Author's Response to "A Letter in Support of Real-World RECIST"

Adv Ther. 2020 Apr;37(4):1691-1693. doi: 10.1007/s12325-020-01246-9. Epub 2020 Feb 13.

Authors

Affiliations

¹ Flatiron Health Inc., New York, NY, USA.
² Genentech, Inc., San Francisco, CA, USA.
³ United States Food and Drug Administration, Silver Spring, MD, USA.
⁴ Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁵ Harvard Medical School, Boston, MA, USA.
⁶ Flatiron Health Inc., New York, NY, USA. ramiksad@flatiron.com.

No abstract available

Keywords: Carcinoma; Endpoints; Immunotherapy; Non-small-cell lung; PD-1; PD-L1; Real-world evidence.

Publication types

Letter
Comment

MeSH terms

Abstracting and Indexing
Carcinoma, Non-Small-Cell Lung*
Electronic Health Records
Humans
Lung Neoplasms*
Response Evaluation Criteria in Solid Tumors
Tumor Burden